Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at ...

Currently priced at approximately $80.53 per share, Haemonetics (HAE) is trading roughly 7.6% below its 52-week ...

Investors in Haemonetics Corporation (NYSE:HAE) had a good week, as its shares rose 6.8% to close at US$68.19 following the release of its annual results. Haemonetics reported US$1.4b in revenue, ...

Loomis Sayles, an investment management company, released its “Small Cap Value Fund” third-quarter 2025 investor letter. A ...

BOSTON, April 2, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, ...

BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the ...

Haemonetics has outperformed the medical device sector, with shares up 7% on very strong revenue growth in plasma collection and good margin leverage. The recent acquisition of OpSens expands ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

We believe that the stock price of Haemonetics (NYSE: HAE), best known for its blood and plasma supplies and services, is undervalued at current levels of $63. HAE stock is down 27% from the levels of ...

BOSTON, March 2, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible ...

Haemonetics is dropping at least $160 million to acquire the maker of a system designed to cool down and protect the esophagus from errant damage during cardiac ablation procedures aimed at ...

The company broadly meets expectations for its Q2 2022 but trims its full-year guidance. Haemonetics booked revenue of $240 million for its second quarter of fiscal 2022, which was 15% higher on a ...